Status: Not yet recruiting
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.
Participants needed: 122
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaUpdated: Mar 13, 2026Locations: 1
Eligibility criteria
Aged at least 18 (or the legal age of consent in the jurisdiction in which the s... [+15]
Pregnancy or breastfeeding. [+2]